TY - JOUR
T1 - Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma
AU - Murakami, Satsuki
AU - Ri, Masaki
AU - Ito, Masato
AU - Nakamura, Nobuhiko
AU - Kasahara, Senji
AU - Kitagawa, Junichi
AU - Inagaki, Yuichiro
AU - Kuroda, Junya
AU - Yoshimitsu, Makoto
AU - Okamoto, Akinao
AU - Fukuhara, Noriko
AU - Taji, Hirofumi
AU - Iida, Hiroatsu
AU - Nagai, Hirokazu
AU - Hanamura, Ichiro
AU - Tsujimura, Hideki
AU - Okura, Miyuki
AU - Kurata, Mio
AU - Kuwatsuka, Yachiyo
AU - Atsuta, Yoshiko
AU - Iida, Shinsuke
N1 - Funding Information:
The study received financial support from Celgene Co., Ltd. We are grateful to the members of the Data and Safety Monitoring Committee of this study, Hirohiko Shibayama, and Yoichi Imai. We are also grateful for the assistance and cooperation of all members at collaborating institutes and the Japanese Data Center for Hematopoietic Cell Transplantation, especially Ms. Noriko Mizutani and Ms. Shizuka Kobayashi, for their assistance with data management.
Funding Information:
The study received financial support from Celgene Co., Ltd. We are grateful to the members of the Data and Safety Monitoring Committee of this study, Hirohiko Shibayama, and Yoichi Imai. We are also grateful for the assistance and cooperation of all members at collaborating institutes and the Japanese Data Center for Hematopoietic Cell Transplantation, especially Ms. Noriko Mizutani and Ms. Shizuka Kobayashi, for their assistance with data management.
Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2022/10
Y1 - 2022/10
N2 - The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1–14, and 20 mg Dex on days 1–2 and 8–9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6–77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8–99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.
AB - The BLd regimen, which is a triplet regimen of bortezomib (Bor), lenalidomide (Len), and dexamethasone (Dex), is effective against newly diagnosed multiple myeloma (NDMM). However, non-hematological toxicities, such as peripheral neuropathy (PN), often hamper long-term continuation of the regimen, particularly in older adult patients. In this study, we examined the efficacy and safety of the modified BLd regimen with reduced-intensity Bor and standard-dose Len. The chemotherapy regimen consisted of 1.3 mg/m2 Bor administered subcutaneously on days 1 and 8, 25 mg Len administered on days 1–14, and 20 mg Dex on days 1–2 and 8–9 of a 3 week cycle for 8 cycles, followed by a 4 week cycle of Dex (40 mg weekly). Among the 30 patients enrolled, 60.0% (95% CI 40.6–77.3) had a very good partial response or better, and the best overall response rate was 96.7% (95% CI 82.8–99.9). Eight patients (26.7%) achieved a complete response. Grade 3 or higher PN was not observed and hematological toxicity was the most common adverse event. The modified BLd regimen showed favorable efficacy with a manageable safety profile, which suggests it could be a treatment option for transplant-ineligible NDMM.
UR - http://www.scopus.com/inward/record.url?scp=85131837483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131837483&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03379-9
DO - 10.1007/s12185-022-03379-9
M3 - Article
C2 - 35699890
AN - SCOPUS:85131837483
VL - 116
SP - 563
EP - 569
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 4
ER -